Literature DB >> 18477210

Aberrant MAD2 expression in soft-tissue sarcoma.

Masanori Hisaoka1, Atsuji Matsuyama, Hiroshi Hashimoto.   

Abstract

Soft-tissue sarcomas can be divided into translocation-associated (TA) and non-TA sarcomas, the latter of which is often characterized by pleomorphic cytomorphology and aneuploidy. The aberrant expression of MAD2, an essential component of the mitotic spindle checkpoint, has been recently shown to promote aneuploidy. The aim of the present paper was to assess MAD2 status on immunohistochemistry in 50 TA sarcomas with known fusion genes and 50 non-TA pleomorphic sarcomas. MAD2 was overexpressed in 26 TA (52%) and 33 non-TA sarcomas (66%). Notably, the MAD2 overexpression was frequently detected in TA sarcomas with atypical or high-grade morphology, such as round cell liposarcoma and fibrosarcomatous dermatofibrosarcoma protuberans. The MAD2 overexpression was significantly frequent in non-TA sarcomas compared with TA tumors without such atypical or high grade morphology (P = 0.012). In addition, sarcomas with MAD2 overexpression were significantly rich in abnormal mitotic figures, including multipolar mitoses and anaphase bridges, compared to MAD2-negative tumors (P = 0.003), although the overall mitotic activity was equivalent between the sarcomas with or without the MAD2 overexpression. These data suggest that the aberrant MAD2 expression is potentially associated with pleomorphic morphology and abnormal mitosis in soft-tissue sarcomas, as well as with high-grade tumor progression in its TA subset.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18477210     DOI: 10.1111/j.1440-1827.2008.02232.x

Source DB:  PubMed          Journal:  Pathol Int        ISSN: 1320-5463            Impact factor:   2.534


  14 in total

1.  Checkpoint-independent stabilization of kinetochore-microtubule attachments by Mad2 in human cells.

Authors:  Lilian Kabeche; Duane A Compton
Journal:  Curr Biol       Date:  2012-03-08       Impact factor: 10.834

Review 2.  Let's huddle to prevent a muddle: centrosome declustering as an attractive anticancer strategy.

Authors:  A Ogden; P C G Rida; R Aneja
Journal:  Cell Death Differ       Date:  2012-06-01       Impact factor: 15.828

Review 3.  Functional characterization of Anaphase Promoting Complex/Cyclosome (APC/C) E3 ubiquitin ligases in tumorigenesis.

Authors:  Jinfang Zhang; Lixin Wan; Xiangpeng Dai; Yi Sun; Wenyi Wei
Journal:  Biochim Biophys Acta       Date:  2014-02-22

4.  Identification of transcription factors (TFs) and targets involved in the cholangiocarcinoma (CCA) by integrated analysis.

Authors:  L Yang; S Feng; Y Yang
Journal:  Cancer Gene Ther       Date:  2016-11-18       Impact factor: 5.987

5.  Depression of MAD2 inhibits apoptosis and increases proliferation and multidrug resistance in gastric cancer cells by regulating the activation of phosphorylated survivin.

Authors:  Li Wang; Fang Yin; Yulei Du; Bei Chen; Shuhui Liang; Yongguo Zhang; Wenqi Du; Kaichun Wu; Jie Ding; Daiming Fan
Journal:  Tumour Biol       Date:  2010-05-04

Review 6.  Mitotic chromosomal instability and cancer: mouse modelling of the human disease.

Authors:  Juan-Manuel Schvartzman; Rocio Sotillo; Robert Benezra
Journal:  Nat Rev Cancer       Date:  2010-02       Impact factor: 60.716

Review 7.  Losing balance: the origin and impact of aneuploidy in cancer.

Authors:  Andrew J Holland; Don W Cleveland
Journal:  EMBO Rep       Date:  2012-06-01       Impact factor: 8.807

8.  MAD2 Expression in Ovarian Carcinoma: Different Expression Patterns and Levels among Various Types of Ovarian Carcinoma and Its Prognostic Significance in High-Grade Serous Carcinoma.

Authors:  Po Eun Park; Ji Yun Jeong; Sun Zoo Kim; Ji Young Park
Journal:  Korean J Pathol       Date:  2013-10-25

9.  p31comet-Induced Cell Death Is Mediated by Binding and Inactivation of Mad2.

Authors:  Hyun-Jin Shin; Eun-Ran Park; Sun-Hee Yun; Su-Hyeon Kim; Won-Hee Jung; Seon Rang Woo; Hyun-Yoo Joo; Su Hwa Jang; Hee Yong Chung; Sung Hee Hong; Myung-Haing Cho; Joong-Jean Park; Miyong Yun; Kee-Ho Lee
Journal:  PLoS One       Date:  2015-11-06       Impact factor: 3.240

10.  Novel Mad2-targeting miR-493-3p controls mitotic fidelity and cancer cells' sensitivity to paclitaxel.

Authors:  Mahesh Tambe; Sofia Pruikkonen; Jenni Mäki-Jouppila; Ping Chen; Bente Vilming Elgaaen; Anne Hege Straume; Kaisa Huhtinen; Olli Cárpen; Per Eystein Lønning; Ben Davidson; Sampsa Hautaniemi; Marko J Kallio
Journal:  Oncotarget       Date:  2016-03-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.